Korea

14 May 2006

As a result of testing fraud, the South Korean Food and Drug Administration is looking at all generics sold in the country. An investigation of 351 generics, tested at 11 locations, revealed that 10 products checked at four sites were approved on the basis of false data, according to a report carried by Chosun Ilbo newspaper and web site, which noted that the original inquiry came after a tip to the agency that some laboratories faked test results. The KFDA also suspects that another 33 generics tested in nine laboratories produced faked data, the report added, however additional inquiries are required since the com-panies are denying the claim. Generics make up 3,907 of the total of 7,689 drugs sold in the country, the news-paper noted.

The four laboratories already identified as having faked tests are run by LabFrontier, the School of Pharmacy of Sungkyunkwan University, BioCore and the Korea Pharmaceutical Traders Association, the newspaper said. The nine that are denying the claims are run by the colleges of pharmacy of Kyung Hee University, Chonnam National University, Chungnam National University, Chung-Ang University and others.

Drug firms told to recall and destroy product

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight